Company profile
Sunshine Biopharma, Inc.
NASDAQ: SBFM · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Pointe-Claire, QCCIK 0001402328Reports USD
#479 of 1,422 Healthcare companies by revenue47th-percentile growth
EA Score
50DFH 56DQ 46GM 50SS 34
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, balance-sheet leverage · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$35.3M
Rev growth YoY (TTM)
-2.7%
Net income (FY)
-$6.0M
Employees
50
as of 2026-08-26
Market cap
$2.7M
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$36.3M$36.3M2025
Net income-$6.0M-$6.0M2025
Operating income-$6.2M-$6.2M2025
Total assets$30.1M$30.1M2025
Liabilities$7.0M$7.0M2025
Equity$23.0M$23.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Sunshine Biopharma, Inc.’s revenue?
Sunshine Biopharma, Inc. booked $36.3M in FY2025 revenue, growing 4.1% year over year — about the middle of the pack among Healthcare companies we track, at a -16.5% net margin.
Peers · Healthcare
Retractable Technologies, Inc.57CCytosorbents Corporation55CClearPoint Neuro, Inc.62CC4 Therapeutics, Inc.49DEarth Science Tech, Inc.69BVerrica Pharmaceuticals Inc.51DKey facts
CEOSteve N. Slilaty
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersPointe-Claire, QC
ExchangeNASDAQ: SBFM
Employees50
IPO date2022-02-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.